lots of potential here. the question long term is how far can this go. The China Play with Eden Cell, is never mentioned. The potential here is Awesome. In country partner in China, with great staff, Scaling up for centralized cost effective treatment in China. Us will be different.
the question in the US is will ZIOP bring this to market on their own or partne, merge with a big pharma
They (PACT) have their own methods of identifying neoantigen-specific T-cells in the blood [1] and use a nonviral (an undisclosed, CRISPR-based approach) which has been translated into a single-step (c)GMP manufacturing process.
The product consist mainly of T-cells of the ''younger'' Tscm [2,3] and Tcm [4] phenotype and are polyfunctional [5]. Also, it contains CD4+ in addition to CD8+ T-cells and we know the former are critical for durable responses [6,7].
Sometime this year they will move to a product that has up to at least four TCRs, their HLA catalog enables analysis for over 99% of the population and clonal neoantigens are prioritised [8].
News 
Market Data 
Discover 
